MET exon 14 skipping mutations occur in 3–4% of lung adenocarcinomas and results in the deletion of the intracellular juxtamembrane domain of the receptor, leading to enhanced signaling and tumor proliferation12,13. This evidence concerns the gene MET and lung adenocarcinoma.